Findings

What do systematic reviews say?

5 questions · 5 findings · 2 reviews · Lung Cancer

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 20%Moderate 1 · 20%High 3 · 60%

Overall survival · People with advanced non‐small cell lung cancer

Epidermal growth factor showed no clear difference in overall survival compared with best supportive care (low certainty).

1 finding from 1 review

Therapeutic vaccines for advanced non‐small cell lung cancer 2024 · Cochrane Headline outcomes only
HR 0.82 [0.66, 1.02]
1 study · 378 participants
Low

Overall survival · EGFR M+ patients with NSCLC

Erlotinib showed no clear difference in overall survival compared with control (high certainty).

1 finding from 1 review

Overall survival · EGFR M+ patients with NSCLC

Gefitinib showed no clear difference in overall survival compared with paclitaxel + carboplatin (high certainty).

1 finding from 1 review

Overall survival · EGFR M+ patients with NSCLC

Gefitinib showed no clear difference in overall survival compared with pemetrexed + carboplatin with pemetrexed maintenance (moderate certainty).

1 finding from 1 review

Overall survival · EGFR M+ patients with NSCLC

Afatinib showed no clear difference in overall survival compared with chemotherapy (high certainty).

1 finding from 1 review